Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT06104124

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity

Sponsor: Amgen

Conditions Sjogren's Syndrome

Interventions Dazodalibep Placebo

Updated 21 times since 2023 Last updated: Jan 14, 2026 Started: Jan 24, 2024 Primary completion: Aug 19, 2026 Completion: Aug 19, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Sjogren's Syndrome and is currently ongoing. Amgen leads this study, which shows 21 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

21 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE3
Oct 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting

▶ Show 16 earlier versions

Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE3
Apr 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE3
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Mar 2024 — May 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2023 — Jan 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Arequipa, Peru , Athens, Greece , Auckland, New Zealand , Augusta, United States , Austin, United States , Avondale, United States , Bad Doberan, Germany , Baytown, United States , Beckley, United States and 160 more locations